Table 2.
Treatment data of the patient collectives and gyne-oncological sub-groups.
| Treatment Parameters | C50 | C51 | C52 | C53 | C54 | C56 | GYN | OB | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019–2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2021 | 2021 | |
| Share of overall oncological patient number, in % | 66.1% | 66.1% | 69.0% | 5.7% | 7.2% | 3.8% | 0.7% | 1.1% | 1.0% | 5.6% | 4.9% | 4.4% | 9.6% | 9.4% | 8.4% | 12.2% | 11.2% | 13.4% | 35.1% (GYN*1) | ||
| Share of overall revenue in oncology, in % | 48.9% | 49.4% | 49.1% | 5.2% | 8.8% | 6.7% | 1.4% | 2.2% | 1.4% | 7.9% | 6.6% | 5.7% | 13.4% | 11.9% | 11.8% | 23.2% | 21.3% | 25.3% | 52.9% (GYN*2) | ||
| Average LoS, in days | 4.8 | 5.1 | 4.7 | 9.1 | 10.8 | 15.7 | 12.6 | 12.1 | 13.6 | 9.5 | 9.5 | 9.5 | 10.3 | 9,6 | 10.5 | 13.6 | 13.4 | 12.9 | 4.6 | 3.9 | |
| LoS-D, in % |
Normal LoS | 90% | 91% | 90% | 79% | 80% | 73% | 80% | 86% | 57% | 85% | 84% | 80% | 83% | 92% | 82% | 87% | 85% | 89% | 75.9% | 74.5% |
| Below limit LoS | 6% | 6% | 7% | 18% | 13% | 12% | 20% | 14% | 14% | 13% | 13% | 17% | 9% | 5% | 13% | 6% | 7% | 4% | 20.3% | 22.5% | |
| Above limit LoS | 4% | 3% | 3% | 3% | 7% | 15% | 0% | 0% | 29% | 3% | 3% | 3% | 8% | 3% | 5% | 7% | 8% | 7% | 3.7% | 3.0% | |
| CMI | 1.5 | 1.3 | 1.2 | 1.8 | 2.0 | 2.9 | 2.8 | 2.3 | 2.2 | 2.8 | 2.3 | 2.2 | 2.8 | 2.1 | 2.4 | 3.8 | 3.2 | 3.2 | 1.1 | 0.6 | |
| PCCL | 0.5 | 0.5 | 0.4 | 0.8 | 1.2 | 1.5 | 1.1 | 1.2 | 1.1 | 1.1 | 1.2 | 1.1 | 1.6 | 1.1 | 1.5 | 2.5 | 2.1 | 2.5 | 0.4 | 0.4 | |
| Average number of SD | 2.0 | 2.8 | 4.7 | 3.6 | 7.8 | 11.3 | 3.9 | 6.3 | 8.5 | 3.9 | 6.3 | 8.5 | 6.2 | 6.3 | 11.1 | 8.0 | 9.4 | 14.9 | 5.3 | 5.5 | |
LoS = length of stay, LoS-D = length of stay distribution of all patients, SD = secondary diagnoses, CMI = case mix index, PCCL = patient clinical complexity level, GYN*1 = gyne-oncology share of total gynecology patients in %, GYN*2 = gyne-oncology share of total revenue in %.